Markets are fascinating because they are ultimately mechanisms for allocating scarce resources.
The stock market allocates capital. Investors continuously decide which companies deserve funding based on their expectations of future value creation. In the long run, markets tend to reward companies capable of generating sustainable profits and penalize those that cannot.
The commercial market works in a similar way, but instead of allocating money from investors, it allocates customers. Companies compete for hospitals, surgeons, healthcare systems, and ultimately patients. Even an outstanding product cannot survive indefinitely without sufficient customers.
The soft-tissue surgical robotics market is a much smaller and far more specialized ecosystem. Here, companies compete not only on technology, but also on regulatory approval, manufacturing capacity, service networks, surgeon training, clinical evidence, reimbursement, and financial sustainability.
And this is where an increasingly important question arises: how many soft-tissue robotic platforms can this market actually sustain?
Over the past decade we have witnessed an explosion of new companies entering the field. Some have already obtained regulatory approval. Others remain in clinical development. And some may never reach commercialization despite remarkable technological achievements. This is not necessarily a story of technological failure. Sometimes a company develops outstanding engineering but simply runs out of time, funding, or commercial opportunities before reaching the finish line.
The history of technology is full of examples where the best engineering solution was not the one that ultimately dominated the market. Surgical robotics is no different.
Today the market leader remains Intuitive Surgical, whose success illustrates what investors value most: a profitable business built on recurring revenue rather than simply selling capital equipment. More than 11,000 installed systems worldwide generate continuous income through instruments, accessories, and service contracts, creating a business model that has proven remarkably resilient.
Meanwhile, dozens of companies have entered the race. Some have obtained CE Mark or FDA clearance. Others continue raising hundreds of millions of dollars in venture capital. A few have reached public markets through IPOs or SPAC mergers. And several have already disappeared.
This should not surprise us. The barriers to entry are enormous.
- Developing a surgical robot requires hundreds of millions of dollars. Regulatory approval may take many years.
- Manufacturing medical devices at scale is extremely demanding.
- Hospitals expect decades of technical support.
- Surgeons require structured training.
- Clinical evidence must continuously accumulate.
- And investors eventually expect a return.
The encouraging news is that the overall market continues to grow rapidly. Independent market analyses estimate that the global surgical robotics market will expand at annual growth rates of roughly 9–16% over the coming decade, driven by increasing adoption of minimally invasive surgery and expanding indications. Growth, however, does not necessarily mean unlimited room for competitors.
History suggests that many technology markets eventually consolidate around a relatively small number of dominant platforms. The winners are rarely determined by technology alone. Execution, financing, timing, manufacturing, clinical adoption, reimbursement, service infrastructure, and customer confidence are equally decisive.
So, what actually determines success in surgical robotics? Technology is only one piece of the puzzle.
J Granell. Jul 22, 2026
PS. Practical examples? Every day. Vicarious Surgical has officially confirmed its shutdown, while Intuitive Surgical began introducing the da Vinci 5 into China, arguably the most important strategic market for the future of surgical robotics. China is rapidly becoming the world’s largest source of new robotic platforms, competing aggressively on cost. Yet the da Vinci 5 arrives with one major differentiator, haptic feedback, still unmatched by any commercially available soft-tissue robotic system. My impression?
If any market can sustain multiple competing platforms, it is China, unique mix of scale and technological momentum.
